Two prospective trials of immunotherapy in thyroid cancer, one of them negative, provided support for precision-medicine approaches that include immunotherapy. The studies were reported simultaneously ...
A phase II study of pemetrexed and pembrolizumab in recurrent and/or metastatic salivary gland malignancies. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does ...
Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge. A recent review published in Genes & Diseases offers a comprehensive ...
HOUSTON ― Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival ...
Genomic landscape and precision therapeutics in follicular thyroid cancer: Insights from the AACR Project GENIE. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results